Monitoring Neurodegeneration in Glaucoma: Therapeutic Implications

Norimitsu Ban, Carla J. Siegfried, Rajendra S. Apte

研究成果: Review article査読

16 被引用数 (Scopus)

抄録

Glaucoma is one of the leading causes of blindness globally, and is characterized by loss of retinal ganglion cells (RGCs). Because vision loss in glaucoma is not reversible, therapeutic interventions early in disease are highly desirable. However, owing to the current limitations in evaluating glaucomatous neurodegeneration, it is challenging to monitor the disease severity and progression objectively, and to design rational therapeutic strategies accordingly. Therefore, there is a clear need to identify quantifiable molecular biomarkers of glaucomatous neurodegeneration. As such, in our opinion, molecular biomarker(s) that specifically reflect stress or death of RGCs, and which correlate with disease severity, progression, and response to therapy, are highly desirable.

本文言語English
ページ(範囲)7-17
ページ数11
ジャーナルTrends in Molecular Medicine
24
1
DOI
出版ステータスPublished - 2018 1
外部発表はい

ASJC Scopus subject areas

  • 分子医療
  • 分子生物学

フィンガープリント

「Monitoring Neurodegeneration in Glaucoma: Therapeutic Implications」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル